Equivalence in intradermal reactions to histamine and compound 48/80 in dogs before and after sedation with dexmedetomidine or a 1:20 combination of medetomidine and vatinoxan.

Background: Intradermal allergen testing (IDAT) is commonly used to formulate allergen-specific immunotherapy, a pillar treatment for canine atopic dermatitis. Many sedatives have shown histaminergic or anti-histaminergic effects and thus been deemed unsuitable for IDAT.

Objective: The goal of this study was to determine whether, in healthy dogs, dexmedetomidine (Dexdomitor) or a 1:20 combination of medetomidine and vatinoxan (Zenalpha) will affect intradermal reactions compared to unsedated dogs.

Comparison between dexmedetomidine and a combination of medetomidine-vatinoxan on muscle tissue saturation in privately-owned adult dogs undergoing intradermal testing.

This double-blinded randomized cross-over study compared the muscle tissue oxygen saturation (StO) measured at the sartorius muscle after intramuscular (IM) injection of dexmedetomidine hydrochloride (HCl) and co-administration of vatinoxan HCl, a peripheral α2-adrenoceptor antagonist, and medetomidine HCl in healthy privately-owned dogs undergoing intradermal testing (IDAT). After written owner consent, dogs received IM injections of either dexmedetomidine (0.5 mg/m, DEX) or medetomidine (1 mg/m) and vatinoxan (20 mg/m) (MVX).

Effect of three doses of nalbuphine on reversal of sedation and cardiopulmonary effects of morphine-acepromazine in healthy dogs.

Objective: To evaluate the efficacy of three doses of nalbuphine in reversing sedative and cardiopulmonary effects of morphine-acepromazine in dogs.

Study Design: Prospective, randomized experimental trial.

Animals: A group of eight healthy Beagle dogs, aged 5-6 years and weighing 12.